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n Abstract: Recognition of breast cancer disparities between African-American and White American women has gener-
ated exciting research opportunities investigating the biologic and hereditary factors that contribute to the observed outcome
differences, leading to international studies of breast cancer in Africa. The study of breast cancer in women with African
ancestry has opened the door to unique investigations regarding breast cancer subtypes and the genetics of this disease.
International research efforts can advance our understanding of race/ethnicity-associated breast cancer disparities within
the USA; the pathogenesis of triple negative breast cancer; and hereditary susceptibility for breast cancer. n
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Advances in travel and communication technologyhave prompted repeated observations that the
world seems to be getting smaller. Individuals and
communities separated by oceans and/or thousands of
miles can share audiovisual as well as live interactions
on a regular basis. These developments have affected
what we know about breast cancer and its disparate
impact on population subsets. The impact of breast
cancer on African-American (AA) compared to White
American/Caucasian (WA) women is characterized by
complex and seemingly paradoxical differences, with
lifetime incidence rates being lower despite higher
mortality rates. International research efforts have
enlightened us regarding the breast cancer burden of
Africa, and it now appears that African ancestry is
associated with inherited susceptibility for specific pat-
terns of disease. AA and sub-Saharan Africans have
shared ancestry as a consequence of the colonial-era
slave trade and African diaspora. This has resulted in
acknowledgement of hereditary contributions to the
multifactorial explanations for similarities in the
breast cancer burden of Africa and AA (1). Differ-
ences in breast cancer incidence/outcome between AA
and WA have historically been ascribed to socioeco-
nomic disadvantages, but recent studies of breast can-
cer subtypes as well as correlations between triple
negative breast cancer (TNBC), hereditary susceptibil-
ity genetic mutations, and African ancestry have
strengthened our understanding of race/ethnicity-asso-
ciated disparities. This review will summarize the cur-
rently available information on breast cancer
disparities related to racial-ethnic identity, taking
ancestral hereditary factors into account.
BREAST CANCER INCIDENCE AND AFRICAN
ANCESTRY
Population-based incidence rates for breast cancer
are lower in AA compared to WA women and breast
cancer appears to be a low-incidence disease in the
continent of Africa. As shown in Figure 1, the lower
lifetime incidence rates for breast cancer among AA
compared to WA women have been documented by
the Surveillance, Epidemiology and End Results
(SEER) Program since its inception several decades
ago. SEER also documents a poorly understood cross-
over in breast cancer age-incidence rates (2). Up to the
age of 45 years, population based incidence rates of
breast cancer are higher for AA compared to WA
women; furthermore, the average age at breast cancer
diagnosis is 62 years for WA compared to only 57 for
AA patients (3). While accurate population-based
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tumor registry data in low- and middle-income coun-
tries (LMIC) are sparse, the existing data suggest that
breast cancer is a low-incidence disease in Africa (4).
Breast cancer patients in Africa also tend to be youn-
ger than those in Europe and North America, with an
average age of 45–48 years (1,5), although this youn-
ger age distribution clearly reflects the unfortunately
shorter life expectancy for populations in LIMC. A
final breast cancer incidence pattern of note is related
to gender. Population-based incidence rates of male
breast cancer are higher among AA compared to WA,
and the frequency of male breast cancer also appears
to be increased for Africans compared to Europeans
(4,6).
BREAST CANCER MORTALITY AND AFRICAN
ANCESTRY
Figure 1 also demonstrates the higher breast cancer
mortality rates that are observed for AA compared to
WA. These population-based mortality differences did
not emerge until nearly 1980, at which point they
begin to decrease for WA but remain mostly
unchanged for AA. Since tamoxifen as endocrine ther-
apy for breast cancer became available in the late
1970s, this pattern likely reflects the fact that fewer
AA breast cancer patients have hormone receptor-
positive disease (discussed below). The mortality dif-
ferences are present in every age category. Figure 2
Figure 1. Population-based breast cancer
incidence and mortality rates in AA and
White American women, from the Surveil-
lance, Epidemiology, and End Results pro-
gram (48). Note that disparities in mortality
curves do not become apparent until mid-
1980s, following availability and adoption of
tamoxifen as systemic therapy for breast
cancer.
Figure 2. International variation in breast
cancer incidence, mortality, and mortality-to-
incidence ratios from Newman (3), Jemal
et al. (49) and Globocan 2008 (50).
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demonstrates the fact that although breast cancer
incidence and mortality are both lower in LMIC
compared to more affluent countries, the mortality-
to-incidence ratios are dramatically higher in socioeco-
nomically disadvantaged populations.
BREAST CANCER PRESENTATION, SUBTYPES,
AND AFRICAN ANCESTRY
The earliest detectable form of breast cancer is the
ductal carcinoma in situ (DCIS) lesion, which is most
commonly detected as a mammographic abnormality.
This pre-invasive disease is associated with 98% sur-
vival rates, and in the discussion of whether African
ancestry is associated with biologically unfavorable
patterns of breast cancer progression, it is reasonable
to compare outcomes for AA versus WA DCIS
patients. No significant data exist regarding DCIS pat-
terns in Africa because of the absence of population-
based mammography screening programs.
Several studies—some population-based, others
from single institutions—have revealed varying degrees
and patterns of treatment failure for DCIS related to
racial/ethnic identity. The largest (7) is a pooled analy-
sis of studies conducted internationally on DCIS out-
comes. This robust composite study demonstrated
worse local and distant survival outcomes for AA
patients. The included SEER-based pooled analyses
revealed a 35% higher overall mortality for AA com-
pared to WA (RR = 1.35; 95% confidence interval
1.12–1.62). Risk of invasive and advanced recurrences
were increased for AA patients.
A SEER analysis by Li et al. (8) evaluated incidence
rates of invasive cancer among patients with a prior
history of DCIS. AA women had more than twice the
risk of being diagnosed with subsequent Stage III/IV
breast cancer compared to WA. Similarly, the Califor-
nia Cancer Registry reported a nearly two-fold higher
relative risk of invasive ipsilateral breast cancer among
AA women previously treated for DCIS (9). AA DCIS
patients had a 1.6 relative risk (95% confidence inter-
val 1.1–2.1) of local recurrence after breast-conserving
surgery among nearly three thousand women treated
in the Cancer Research Network, a consortium of 14
integrated health care delivery systems (10). The M.D.
Anderson Cancer Center (MDACC) (11,12) and the
Henry Ford Health System (13) have both reported
DCIS outcomes related to racial/ethnic identity. The
two studies from MDACC had seemingly contrasting
results. In their retrospective analysis of nearly two
thousand DCIS patients (74% WA; 11% AA; 9% His-
panic; and 5% Asian/Pacific Islander) with 4.8 years
median follow-up, there were no race/ethnicity-related
outcome differences, but the Hispanic patients tended
to be younger than the AA and WA patients (11).
However, a separate analysis looked at 25 patients
experiencing distant metastatic disease among 2,123
cases of pure DCIS (frequency of distant metastasis
0.14%). Interestingly, AA accounted for 24% of the
patients with metastatic disease, despite accounting
for only 11.5% of the total DCIS population (12).
Stark et al. (13) evaluated the diverse cohort of 336
DCIS cases (30% AA) from the Henry Ford Health
System in Detroit, Michigan. With a mean follow-up
time of nearly 5 years, the risk of ipsilateral second
cancers was 3.96 for the AA patients (95% confidence
interval 1.42–11.04; p = 0.01), but the risk of contra-
lateral new breast cancers was similar for both groups.
As noted above, disparities in breast cancer mortal-
ity rates between AA and WA became apparent
approximately 30 years ago, following the advent of
tamoxifen as adjuvant therapy for breast cancer. Once
hormone receptor testing became standard, differences
in breast cancer patterns were documented, with AA
women having an approximately two-fold higher fre-
quency of hormone receptor negative disease com-
pared to WA women. Routine immunohistochemistry
for evaluation of HER2/neu over the past 10 years
has led to extensive research regarding tumors that
are negative for the estrogen receptor, the progester-
one receptor, and HER2/neu, commonly referred-to as
TNBC. The TNBC phenotype accounts for 15% of
WA breast cancer patients compared to approximately
30% of the tumors in AA. TNBC tends to be a more
challenging pattern of disease because it is not amena-
ble to therapy with targeted systemic treatments, and
also because the majority belongs to the inherently
aggressive basal breast cancer subtype as defined by
gene expression studies (14–17).
International studies have furthermore revealed
that breast cancer patients from sub-Saharan Africa
have some of the highest frequencies of TNBC com-
pared to any other populations in the world. Table 1
summarizes studies reporting frequencies of TNBC
among various population subsets within the USA
and internationally. Interestingly, data from the
population-based California Cancer Registry have
also demonstrated higher frequencies of TNBC
among AA men with breast cancer compared to WA
men with breast cancer (18).
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Recent epidemiologic research reveals that clinical
and reproductive risk factors differ for TNBC versus
non-TNBC. Multiparity, for example, has long been
accepted as protecting against breast cancer develop-
ment, but subset analyses show that multiple pregnan-
cies only reduce the risk of hormone receptor-positive/
non-TNBC (19–24). Several of these studies show that
multiparity increases likelihood of being diagnosed
with TNBC (19,21,23,24). The association between
childbearing patterns and TNBC prompts speculation
that multiparity might account for the increased bur-
den of TNBC observed in sub-Saharan Africa, since
women in LMIC tend to start childbearing at rela-
tively young ages and they tend to have multiple preg-
nancies. It is noteworthy however that as shown in
Table 1, frequencies of TNBC are nonetheless higher
in sub-Saharan Africa compared to other LMIC in
Asia and northern Africa, where the child-bearing pat-
terns are likely to be similar.
BREAST CANCER IN AA WOMEN: IMPLICATIONS
FOR SCREENING MAMMOGRAPHY
RECOMMENDATIONS
Race/ethnicity-associated differences in population-
based incidence of TNBC are also relevant to the
controversial discussion of breast cancer surveillance
and the age at which American women should initiate
screening mammography. In November 2009 (25) the
United States Preventive Services Task Force (USPSTF)
published a reevaluation of the historic prospective
randomized clinical trials conducted 20–30 years ago,
comparing screening mammography to “usual medical
care.” As a result of this reevaluation, the USPSTF
recommended that American women initiate screening
mammography at age 50 years rather than 40. They
neglected to comment on the potential impact of
delayed screening on AA women, who face an
increased risk of TNBC as well as an increased risk of
early-onset disease. As shown by Amirikia et al.
(Fig. 3) in a study from the California Cancer Registry
(26), population-based incidence rates of TNBC for
AA women in the 40–49 year age range is comparable
to those of WA women in the 60–69 year age range.
TNBC IN WOMEN WITH AFRICAN ANCESTRY:
IMPLICATIONS FOR GENETIC COUNSELING/
TESTING
Triple negative breast cancer is known to be a mar-
ker of hereditary breast cancer susceptibility syn-
dromes, such as BRCA1 mutations. In the early years
of BRCA gene sequencing, little was known about fre-
quency of BRCA mutations among AA pedigrees fea-
turing strong family histories of breast and/or ovarian
cancer. In light of correlations between TNBC and
AA identity, more AA families are undergoing genetic
counseling and testing, revealing that BRCA mutations
Table 1. Frequency of Triple Negative Breast
Cancer in Various Countries and Population
Subsets
Country Study TNBC (%)
Kenya Trinkaus et al. 2011 (54) 32
Uganda Roy and Othieno 2011 (55) 36
Ghana Stark et al. 2010 (5) 82
Kenya Bird et al. 2008 (56) 44
Sudan Awadelkarim 2011 16
Tunisia Abdelkrim 2010 18
India Ambroise 2011 25
Malaysia Teoh 2011 15
Malaysia Tan 2009 18
India Ghosh 2011 29
Indonesia Ng 2011 21
Canada Dent et al. 2007 (57) 11
Turkey Turkoz et al. 2013 (58) 12
Greece Fostira et al. 2012 (59) 8
China Song et al. 2013 (60) 22
USA Carey et al. 2006 (61) AA (premenopausal): 39
WA: 16
Morris et al. 2007 (62) AA: 21
WA: 10
Lund et al. 2009 (63) AA: 47
WA: 22
Moran et al. 2008 (64) AA: 21
WA: 8
Chavez-Macgregor et al. 2013 (18) AA Males: 9
WA Males: 3
Figure 3. Population-based incidence rates of triple negative
breast cancer stratified by age range at diagnosis, from California
Cancer Registry (51).
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are more common than previously thought. Table 2
summarizes the results of studies that have evaluated
frequency of BRCA mutations in AA. Hurley (27,28)
identified a BRCA1 founder mutation unique to
Caribbean women with African ancestry, based upon
genetic testing in a series of patients from the Baha-
mas. It is furthermore plausible that low- and moder-
ate-risk genetic variants exist that collectively
contribute to the breast cancer burden of selected pop-
ulation subsets (29,30).
Despite the notably high frequency of TNBC in
sub-Saharan Africa, little is known about prevalence
of BRCA mutations in this part of the continent.
International patterns of BRCA1 and BRCA2 muta-
tions were recently and comprehensively reviewed by
Karami and Mehdipour (31). Most of the data regard-
ing BRCA mutations in Africa are based upon north-
ern African populations, with only one study each
representing Nigeria and South Africa.
TNBC IN WOMEN WITH AFRICAN ANCESTRY:
RESEARCH IMPLICATIONS
Figure 4 summarizes the results of existing data
regarding the features of breast cancer as it afflicts
AA, WA, and sub-Saharan African women. With
regard to average age at diagnosis, frequency of
adverse tumor features, and frequency of male breast
cancer, a consistent pattern is seen with AA women
always intermediate in extent of these features. This
pattern suggests that extent of African ancestry is
indeed associated with likelihood of expressing certain
patterns of breast cancer, and this theory is hypothe-
sis-generating for a variety of research studies investi-
gating the pathogenesis of TNBC.
Fejerman et al. (32) performed admixture scans in
nearly 1,500 AA breast cancer patients and confirmed
that extent of African ancestry was associated with
risk of hormone receptor-negative disease, but no spe-
cific ancestral marker predicting susceptibility for dis-
ease was identified. More recently, several genotyping
analyses from the Black Women’s Health Study have
identified SNPs and patterns associated with African
ancestry that are also correlated with risk of TNBC
(33–35).
Breast cancer studies from the University of Michi-
gan-Ghana breast cancer partnership have also identi-
fied novel patterns of molecular marker expression
associated with mammary stem cells in sub-Saharan
African populations. The mammary stem cell marker
ALDH1 was found to be elevated in Ghanaian benign
as well as malignant breast specimens (36), and the
marker EZH2 was also found to have unique patterns
in Ghanaian breast tissue compared to WA breast
cancer patients (37).
Advances in gene expression studies are now dem-
onstrating that TNBC is a heterogeneous breast cancer
subset, characterized by distinct subtypes featuring
tumor progression through specific pathways. The
Vanderbilt group (38,39) identified at least six differ-
ent TNBC subtypes: two basal-like; one immuno-
modulatory; one mesenchymal; one mesenchymal
stem cell-like; and one luminal androgen receptor).
These subtypes are associated differential response to
neo-adjuvant chemotherapy (40,41) and may serve
as a basis for targeted antiandrogen therapy with
Table 2. Frequency of BRCA Mutations in AA and
Bahamian Breast Cancer Patients
Study, year
Proportion of patients with BRCA mutation
(study population)
Akbari et al. 2014 (28) 27% (58/214 Bahamian patients unselected
for age or family history)
Sharma et al. 2014 (65) 7% (2/30 TNBC patients)
Greenup et al. 2013 (66) 20% (17/83 TNBC patients)
Pal et al. 2013 (67) 41% pathogenic; 35% VUS (3/46 pathogenic
variants; 16/46 VUS)
Donenberg et al. 2011 (27) 23% (49/214 Bahamian patients unselected
for age or family history)
Nanda et al. 2005 (68) 28% pathogenic; 44% VUS (7/43 high-risk
families with pathogenic BRCA1 mutation;
5/43 high-risk families with pathogenic
BRCA2 mutation; and 19/43 high-risk
families with VUS)
Gao et al. 2000 (69) 18% (5/28 oncology clinic patients)
Gao et al. 1997 (70) 56% (5/9 high-risk patients with BRCA1
mutation)
TNBC, triple negative breast cancer; VUS, variant of unknown significance.
Figure 4. Frequency of breast cancer patterns in AA, Caucasian/
White Americans, and African populations (3,52,53).
Breast Cancer Disparities • 137
bicalutamide (42–46) for the luminal androgen recep-
tor-positive TNBC. Preliminary data suggest novel
patterns of androgen receptor expression in Ghanaian
women (47) and additional research is necessary in
the study of TNBC subtypes among women with Afri-
can ancestry.
SUMMARY
The study of breast cancer in women with African
ancestry has opened the door to unique research
opportunities regarding subtypes and the genetics of
this disease. International research efforts can advance
our understanding of the pathogenesis of TNBC as
well as hereditary susceptibility for breast cancer.
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